Patient Access & Engagement · Healthcare & Life Sciences
Should you build or buy Remote Patient Monitoring (RPM) Platform?
Remote patient monitoring (RPM) platforms connect FDA-registered medical devices to clinical workflows — enrolling patients with chronic conditions, collecting vitals in the home, alerting care coordinators when readings cross thresholds, and managing the CMS billing codes that make monitoring reimbursable.
The build-vs-buy decision for Remote Patient Monitoring Platform turns on the degree to which the value in this category comes from software logic versus FDA device certification, CMS billing compliance, and cellular connectivity logistics — and how much of what vendors sell is infrastructure a team simply cannot replicate.
Build it, buy it, or bridge?
When building makes sense
Full self-build in RPM is not a practical path for most organizations, and the reasoning is specific: what vendors like Cadence, Prevounce, and Health Recovery Solutions sell is not primarily software workflow — it's the combination of FDA-registered device libraries, cellular connectivity logistics, and CMS billing code management that turns monitoring data into reimbursable revenue. Those assets aren't achievable through a software build. The FDA device registration process, the cellular data plans for patient devices, and the CMS compliance maintenance are infrastructure problems that no independent team has solved from scratch. Where building is viable and genuinely valuable is at the analytics and clinical decision support layer above the vendor data stream. Organizations with growing longitudinal vitals datasets can build AI-driven risk stratification, population health overlays, and predictive alert models that a vendor's standard threshold-based alerting doesn't cover. The data is the asset — what you build on top of it is where differentiation becomes possible.
When buying makes sense
Buying is the correct path for virtually every organization entering RPM, because the core value in this category is infrastructure that vendors have spent years assembling. FDA-registered device catalogs, cellular connectivity for home use, and CMS RPM billing code management are operational requirements that no practice or health system builds independently. The practical decision is vendor selection, not build-versus-buy. Prevounce and HealthSnap cover primary care and chronic condition management at scale. Cadence skews toward cardiology and higher-acuity remote monitoring. Biofourmis brings deeper clinical analytics for complex conditions. The choice turns on which device catalog matches your target conditions (hypertension, CHF, diabetes, COPD), which connectivity model fits your patient population's technology access, and which billing automation approach fits your existing revenue cycle. AI is beginning to add risk stratification from longitudinal vitals data, which creates downstream analytical value, but it sits on top of the same vendor device and billing infrastructure for the foreseeable future.
The desk read
RPM's build-vs-buy question resolves quickly when you look at what the category actually sells. The software workflow for enrollment, alert routing, and care coordinator handoffs is generic. What vendors like Cadence and Health Recovery Solutions sell is the combination of FDA-registered device libraries, cellular connectivity logistics, and CMS billing code management that turns monitoring data into reimbursable revenue. That package isn't a software build problem.
The practical decision for most health systems and large practices is which vendor's device catalog matches their target conditions (hypertension, CHF, diabetes, COPD) and which connectivity model (cellular-first vs. Bluetooth) fits their patient population's tech literacy. Biofourmis skews toward higher-acuity remote cardiology monitoring; Prevounce and HealthSnap skew toward primary care and chronic condition management at scale. AI is beginning to feed into risk stratification from longitudinal vitals data, which adds downstream analytical value over time but doesn't change the near-term vendor dependency on the device and billing infrastructure.
Frequently asked
What is a Remote Patient Monitoring (RPM) Platform?
Remote patient monitoring (RPM) platforms connect FDA-registered medical devices to clinical workflows — enrolling patients with chronic conditions, collecting vitals in the home, alerting care coordinators when readings cross thresholds, and managing the CMS billing codes that make monitoring reimbursable.
When does building a Remote Patient Monitoring Platform make sense?
Full self-build isn't a realistic path because FDA device certification, cellular connectivity logistics, and CMS billing compliance aren't software problems. Where building makes sense is at the analytics layer above a vendor's data stream — AI risk stratification and population health models that standard threshold alerting doesn't cover.
When does buying a Remote Patient Monitoring Platform make sense?
Buying is the right path for almost every organization, because the core value — FDA-registered device libraries, home cellular connectivity, and CMS billing code management — is infrastructure vendors have built over years that no internal team replicates.
What are the main Remote Patient Monitoring Platform vendors?
Representative vendors include Prevounce Health, Cadence, Health Recovery Solutions (HRS), HealthSnap. B4 Pro scores the full set.
How should an organization choose between RPM vendors?
The key selection variables are device catalog match (which conditions you're monitoring), connectivity model (cellular-first versus Bluetooth based on your patient population's tech access), and billing automation approach. Prevounce and HealthSnap cover primary care scale; Cadence and Biofourmis skew toward higher-acuity cardiology and complex condition monitoring.